Biophytis (BPTSY) trading halted as 2025 annual report faces delay
Rhea-AI Filing Summary
Biophytis SA announced that trading of its shares on Euronext Growth Paris has been temporarily suspended. Euronext took this step because the company did not publish its annual financial report for the fiscal year ended December 31, 2025, on time due to an operational delay in preparing the financial statements.
The annual report will be released after the accounts are certified by the statutory auditors, which the company expects to occur by the end of July 2026. Trading is expected to resume once the annual financial report has been published, and Biophytis plans to inform the market of the specific resumption date.
Positive
- None.
Negative
- Temporary trading suspension: Euronext Growth Paris has suspended trading of Biophytis shares following a delay in publishing the annual financial report for the year ended December 31, 2025, limiting short-term liquidity and price discovery.
Insights
Trading in Biophytis shares is halted until late financials are certified.
Biophytis is facing a temporary trading suspension on Euronext Growth Paris because its annual financial report for the year ended December 31, 2025 was not published on schedule, citing an operational delay in preparing the financial statements.
The company states the report will be released after statutory auditors certify the accounts, with timing expected no later than the end of July 2026. Trading is expected to resume once the report is published, so the practical impact depends on how long the suspension lasts.
For now, the event mainly affects liquidity and short-term access to the stock rather than providing insight into business performance. Subsequent disclosures in the certified annual financial report will be important to understand the company’s financial position as of year-end 2025.
Key Figures
Key Terms
temporary suspension regulatory
annual financial report financial
statutory auditors financial
clinical-stage biotechnology company financial
UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: June 16, 2026
Commission File Number: 001-38974
BIOPHYTIS S.A.
(Translation of registrant’s name into English)
Stanislas Veillet
Biophytis S.A.
Sorbonne University—BC 9, Bâtiment A 4ème étage
4 place Jussieu
75005 Paris, France
+33 1 44 27 23 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
x Form 20-F ¨ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On June 15, 2026, Biophytis S.A. issued a press release announcing the temporary suspension of the trading of its shares. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.
EXHIBIT LIST
| Exhibit | Description | |
| 99.1 | Press Release dated June 15, 2026. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIOPHYTIS S.A. | ||
| Date: June 16, 2026 | By: | /s/ Stanislas Veillet |
| Name: Stanislas Veillet | ||
| Title: Chairman and Chief Executive Officer | ||
Exhibit 99.1
BIOPHYTIS ANNOUNCES THE TEMPORARY
SUSPENSION OF THE TRADING OF ITS SHARES
Paris (France) and Cambridge (Massachusetts, U.S.), June 15, 2026, at 11:00 p.m CET. – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces the temporary suspension of the trading of its shares by Euronext.
This suspension results from the non-publication of the annual financial report for the fiscal year ended December 31, 2025, due to an operational delay in the preparation of the financial statements. The report will be published following certification of the accounts by the statutory auditors, which is expected no later than the end of July 2026.
Trading of Biophytis shares on Euronext Growth Paris was suspended on June 15, 2026, and is expected to resume following the publication of the annual financial report. The Company will keep the market informed of the date on which trading will resume.
* * *
About Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age- related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.
Biophytis Contact
Investor relations
investors@biophytis.com
Media relations
Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr – +33 6 38 31 90 50